Innoviva (NASDAQ:INVA) Fits the Affordable Growth Mold
Innoviva Inc INVA
$21.11
▼ -0.57%
($-0.12)
Open
$21.19
Prev Close
$21.23
Day Range
$20.74 – $21.19
52W Range
$16.52 – $25.15
Market Cap
$1.53B
P/E (TTM)
4.24
Beta
0.39
EPS (TTM)
$4.05
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-10-05 |
| Shares Out. | 73,810,000 |
| Website | inva.com/ ↗ |
| Phone | 13026587581 |
| Employees | 159 |
| Revenue | $119.6M |
| Gross Profit | $97.2M |
| Net Income | -$83.4M |
| Free Cash Flow | $189.4M |
| Total Assets | $1.70B |
| Total Liabilities | $469.5M |
| Equity | $1.23B |
About Innoviva Inc
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Innoviva Inc is a publicly traded company under the ticker symbol INVA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-09-01)